Genmab aktie (GMAB) | Pressmeddelande

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

GlobeNewswire • 11 Dec 2024 14:20

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combinati...

GlobeNewswire • 09 Dec 2024 18:00

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients ...

GlobeNewswire • 08 Dec 2024 17:00

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Rela...

GlobeNewswire • 08 Dec 2024 01:12

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 03 Dec 2024 22:35

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

GlobeNewswire • 03 Dec 2024 13:07

Genmab to Present at Citi’s Global Healthcare Conference

GlobeNewswire • 25 Nov 2024 17:06

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 21 Nov 2024 20:48

Genmab Announces Financial Results for the First Nine Months of 2024

GlobeNewswire • 06 Nov 2024 17:02

Genmab to Present at Jefferies London Healthcare Conference

GlobeNewswire • 05 Nov 2024 19:11

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) A...

GlobeNewswire • 05 Nov 2024 18:00

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

GlobeNewswire • 15 Oct 2024 12:25

Major Shareholder Announcement

GlobeNewswire • 04 Oct 2024 19:55

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 26 Sep 2024 21:17

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovaria...

GlobeNewswire • 15 Sep 2024 14:45

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 10 Sep 2024 22:06

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire • 26 Aug 2024 18:26

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphom...

GlobeNewswire • 19 Aug 2024 20:00

Genmab Announces Changes to its Executive Committee

GlobeNewswire • 16 Aug 2024 15:00

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 13 Aug 2024 20:53

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 13 Aug 2024 20:51

Genmab Announces Financial Results for the First Half of 2024

GlobeNewswire • 08 Aug 2024 17:03

Genmab Updates 2024 Financial Guidance

GlobeNewswire • 08 Aug 2024 17:00

Genmab Takes Full Control of Acasunlimab Development Program

GlobeNewswire • 05 Aug 2024 11:50

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

GlobeNewswire • 17 Jul 2024 12:25

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

GlobeNewswire • 28 Jun 2024 08:00

Completion of Share Buy-back Program

GlobeNewswire • 27 Jun 2024 23:00

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

GlobeNewswire • 27 Jun 2024 01:03

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 24 Jun 2024 15:55

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 18 Jun 2024 20:45

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 17 Jun 2024 15:33

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 12 Jun 2024 21:45

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 11 Jun 2024 20:50

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 10 Jun 2024 16:18

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire • 05 Jun 2024 18:51

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 03 Jun 2024 15:09

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and...

GlobeNewswire • 03 Jun 2024 15:00

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate i...

GlobeNewswire • 02 Jun 2024 23:30

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 T...

GlobeNewswire • 01 Jun 2024 16:00

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 27 May 2024 16:16

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire • 23 May 2024 23:00

Genmab Completes Acquisition of ProfoundBio

GlobeNewswire • 21 May 2024 17:06

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 21 May 2024 13:19

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 202...

GlobeNewswire • 14 May 2024 16:02

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 13 May 2024 16:09

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 07 May 2024 20:27

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 06 May 2024 16:01

Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire • 02 May 2024 17:01

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

GlobeNewswire • 30 Apr 2024 00:40

Transactions in Connection with Share Buy-back Program Genmab

GlobeNewswire • 29 Apr 2024 10:24

Transactions in Connection with Share Buy-back Program Genmab

GlobeNewswire • 22 Apr 2024 09:30

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

GlobeNewswire • 16 Apr 2024 12:24

Transactions in Connection with Share Buy-back Program Genmab

GlobeNewswire • 15 Apr 2024 10:07

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 08 Apr 2024 11:44

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

GlobeNewswire • 03 Apr 2024 07:34

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 02 Apr 2024 09:24

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 25 Mar 2024 14:31

Completion of share buy-back program

GlobeNewswire • 18 Mar 2024 10:49

Genmab Announces Initiation of Share Buy-Back Program

GlobeNewswire • 15 Mar 2024 13:16

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 13 Mar 2024 21:58

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants t...

GlobeNewswire • 13 Mar 2024 21:53

Passing of Genmab A/S’ Annual General Meeting

GlobeNewswire • 13 Mar 2024 16:13

Transactions in connection with share buy-back program

GlobeNewswire • 11 Mar 2024 10:42

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 04 Mar 2024 19:10

Transactions in connection with share buy-back program

GlobeNewswire • 04 Mar 2024 10:29

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 02 Mar 2024 00:04

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 29 Feb 2024 16:48

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 27 Feb 2024 21:42

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 27 Feb 2024 21:40

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relaps...

GlobeNewswire • 27 Feb 2024 01:45

Transactions in connection with share buy-back program

GlobeNewswire • 26 Feb 2024 11:21

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 23 Feb 2024 23:50

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

GlobeNewswire • 23 Feb 2024 23:35

Transactions in connection with share buy-back program

GlobeNewswire • 19 Feb 2024 10:40

Notice to Convene the Annual General Meeting of Genmab A/S

GlobeNewswire • 15 Feb 2024 12:00

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

GlobeNewswire • 14 Feb 2024 20:09

Genmab Announces Initiation of Share Buy-Back Program

GlobeNewswire • 14 Feb 2024 17:41

Genmab Publishes 2023 Annual Report

GlobeNewswire • 14 Feb 2024 17:02

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervic...

GlobeNewswire • 02 Feb 2024 12:45

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 25 Jan 2024 20:22

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023

GlobeNewswire • 23 Jan 2024 12:24

Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen

GlobeNewswire • 23 Jan 2024 00:40

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.

GlobeNewswire • 09 Jan 2024 12:45

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

GlobeNewswire • 03 Jan 2024 06:55

Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire • 02 Jan 2024 15:52

Genmab to Hold 2023 R&D Update and ASH Data Review Meeting

GlobeNewswire • 12 Dec 2023 13:00

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with H...

GlobeNewswire • 09 Dec 2023 18:00

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 05 Dec 2023 23:26

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lympho...

GlobeNewswire • 27 Nov 2023 13:00

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 21 Nov 2023 22:45

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

GlobeNewswire • 21 Nov 2023 22:42

Major Shareholder Announcement

GlobeNewswire • 09 Nov 2023 15:14

Genmab to Present at Jefferies London Healthcare Conference

GlobeNewswire • 09 Nov 2023 11:00

Major Shareholder Announcement

GlobeNewswire • 08 Nov 2023 17:09

Genmab Announces Financial Results for the First Nine Months of 2023

GlobeNewswire • 07 Nov 2023 17:01

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

GlobeNewswire • 02 Nov 2023 14:05

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared ...

GlobeNewswire • 22 Oct 2023 16:30

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023

GlobeNewswire • 17 Oct 2023 12:22

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 28 Sep 2023 20:38

Börskollen

För dig med koll på börsen

Pressmeddelanden från Genmab

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab to Present at Citi’s Global Healthcare Conference

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab to Present at Jefferies London Healthcare Conference

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Major Shareholder Announcement

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab Announces Changes to its Executive Committee

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab Announces Financial Results for the First Half of 2024

Genmab Updates 2024 Financial Guidance

Genmab Takes Full Control of Acasunlimab Development Program

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Completion of Share Buy-back Program

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions in Connection with Share Buy-back Program

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

Transactions in Connection with Share Buy-back Program

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Transactions in Connection with Share Buy-back Program

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab Completes Acquisition of ProfoundBio

Transactions in Connection with Share Buy-back Program

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Genmab Announces Financial Results for the First Quarter of 2024

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program

Completion of share buy-back program

Genmab Announces Initiation of Share Buy-Back Program

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Passing of Genmab A/S’ Annual General Meeting

Transactions in connection with share buy-back program

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions in connection with share buy-back program

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Capital Increase in Genmab as a Result of Employee Warrant Exercise

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

Transactions in connection with share buy-back program

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Transactions in connection with share buy-back program

Notice to Convene the Annual General Meeting of Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission